QT Interval Prolongation and Second-line Antituberculosis Medicines in Children: An Update and Practical Considerations for Noncardiologists

Affiliations

¹ Department of Pediatrics, University of Wisconsin-Madison, School of Medicine and Public Health, Madison, Wisconsin.
² National TB Control Program, Mozambique Ministry of Health, Maputo, Mozambique.
³ Department of Pediatrics, University of California Los Angeles David Geffen School of Medicine, Maputo, Mozambique.
⁴ New York University Grossman School of Medicine, New York, New York.
⁵ Department of Paediatrics and Child Health, Desmond Tutu TB Centre, Faculty of Medicine and Health Sciences, Stellenbosch University, Stellenbosch, South Africa.

Jennifer Hughes et al. Pediatr Infect Dis J. 2023.

. 2023 Mar 1;42(3):e80-e83.

doi: 10.1097/INF.0000000000003742. Epub 2023 Feb 3.

¹ Department of Pediatrics, University of Wisconsin-Madison, School of Medicine and Public Health, Madison, Wisconsin.
² National TB Control Program, Mozambique Ministry of Health, Maputo, Mozambique.
³ Department of Pediatrics, University of California Los Angeles David Geffen School of Medicine, Maputo, Mozambique.
⁴ New York University Grossman School of Medicine, New York, New York.
⁵ Department of Paediatrics and Child Health, Desmond Tutu TB Centre, Faculty of Medicine and Health Sciences, Stellenbosch University, Stellenbosch, South Africa.

No abstract available

Conflict of interest statement

The authors have no funding or conflicts of interest to disclose.

1. Roden DM. Drug-induced prolongation of the QT interval. N Engl J Med. 2004;350:1013–1022.
1. Goldenberg I, Moss AJ, Zareba W. QT interval: how to measure it and what is “normal”. J Cardiovasc Electrophysiol. 2006;17:333–336.
1. WHO Consolidated Guidelines on Tuberculosis Module 5: Management of tuberculosis in children and adolescents. 2022. Available at: https://www.who.int/publications/i/item/9789240046764 . Accessed March 27, 2022.
1. Garcia-Prats AJ, Draper HR, Finlayson H, et al. Clinical and cardiac safety of long-term levofloxacin in children treated for multidrug-resistant tuberculosis. Clin Infect Dis. 2018;67:1777–1780.
1. Radtke KK, Hesseling AC, Winckler JL, et al. Moxifloxacin Pharmacokinetics, cardiac safety, and dosing for the treatment of rifampicin-resistant tuberculosis in children. Clin Infect Dis. 2022;74:1372–1381.